| GRÜNENTHAL GMBH Patent applications |
| Patent application number | Title | Published |
|---|
| 20120136021 | OXIDATION-STABILIZED TAMPER-RESISTANT DOSAGE FORM - A thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N,
| 05-31-2012 |
| 20120135071 | Abuse-proofed dosage form - A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid. | 05-31-2012 |
| 20120101079 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS - Substituted 6-amino-nicotinamides, pharmaceutical compositions containing these compounds and also use of these compounds in the treatment and/or prophylaxis of pain and further diseases and/or disorders. | 04-26-2012 |
| 20120065220 | Tamper Resistant Dosage Form Comprising An Anionic Polymer - A pharmaceutical dosage form and method of using same, the pharmaceutical dosage form exhibiting a breaking strength of at least 500 N, said dosage form containing
| 03-15-2012 |
| 20120059066 | PHARMACEUTICAL SALTS - The invention relates to pharmaceutical salts comprised of a pharmaceutical active substance and of at least one sugar substitute, to medicaments containing these salts, and to the use of these salts for producing medicaments. | 03-08-2012 |
| 20120046272 | Novel Therapeutic Compounds - The present invention describes a series of therapeutically active compounds of formula I, | 02-23-2012 |
| 20120028936 | ORAL CONTRACEPTION WITH TRIMEGESTONE - The invention relates to a method for contraception comprising the administration of trimegestone to a woman of child-bearing age on at least 21 successive days, beginning on day 1 of the menstrual cycle, wherein on at least one of the at least 21 successive days the daily dose of trimegestone is more than 500 μg. | 02-02-2012 |
| 20120015031 | NOVEL GASTRO-RETENTIVE DOSAGE FORMS - A gastro-retentive pharmaceutical dosage form comprising a therapeutically effective amount of at least one opioid, at least one form of acetaminophen, optionally an opioid antagonist and at least one pharmaceutically acceptable excipient, which dosage form is retained in the stomach for at least four hours and is suitable for once daily or twice daily administration. Also provided is a method of treating pain by administering the dosage form to a patient in need thereof. The acetaminophen is either in slow release form or in immediate release form or as combination of both. | 01-19-2012 |
| 20110306600 | NOVEL THERAPEUTIC COMPOUNDS - The invention discloses a number of therapeutic compounds and a method of treating a disorder in mammal. | 12-15-2011 |
| 20110187017 | PREPARATION OF A POWDERY PHARMACEUTICAL COMPOSITION BY MEANS OF AN EXTRUDER - The invention relates to a method for the preparation of a powdery pharmaceutical composition comprising a pharmaceutical excipient and a pharmaceutical component, the method comprising the step of extruding a mixture of the pharmaceutical excipient and the pharmaceutical component in an extruder at a temperature profile allowing a liquid melt of the mixture to congeal in the extruder and to exit the extruder in form of a powder. | 08-04-2011 |
| 20110172197 | Dosace Form For Hormonal Contraceptive - A dosage form for hormonal contraception containing a given number of hormone-containing daily units and a given number of hormone-free daily units for daily, oral administration, where the hormone-containing daily units each contain at most the minimum effective daily amount of folic acid for women and the hormone-free daily units contain at least a multiple of this amount up to the maximum permissible amount of folic acid for women. | 07-14-2011 |
| 20110059999 | Hydroxymethylcyclohexylamines - The invention relates to compounds which have an affinity for the μ opioid receptor and the ORL1 receptor, processes for the preparation thereof, medicaments containing these compounds and the use of these compounds for the preparation of medicaments. | 03-10-2011 |
| 20110038930 | HOT-MELT EXTRUDED PHARMACEUTICAL DOSAGE FORM - The invention relates to a hot-melt extruded pharmaceutical dosage form with controlled release of a pharmacologically active ingredient (A) embedded in a matrix comprising a polymer (C), the dosage form exhibiting a breaking strength of at least 300 N and having an oblong shape comprising a longitudinal direction of extension, a transversal direction of extension orthogonal to the longitudinal direction of extension, a front side, an opposite back side and a circumferential rim between said front and back side; | 02-17-2011 |
| 20110020451 | TAMPER-RESISTANT DOSAGE FORM FOR OXIDATION-SENSITIVE OPIOIDS - Thermoformed pharmaceutical dosage form having a breaking strength of at least 300 N, comprising
| 01-27-2011 |
| 20110015220 | MIXED ORL1/MU-AGONISTS FOR THE TREATMENT OF PAIN - The invention relates to the use of compounds which exhibit an affinity for the μ-opioid receptor of at least 100 nM (K | 01-20-2011 |
| 20100279989 | ORAL CONTRACEPTION WITH TRIMEGESTONE - The invention relates to a method for contraception comprising the administration of trimegestone to a woman of child-bearing age on at least 21 successive days, beginning on day 1 of the menstrual cycle, wherein on at least one of the at least 21 successive days the daily dose of trimegestone is more than 500 μg. | 11-04-2010 |
| 20100260833 | ABUSE-PROOFED DOSAGE FORM - The invention relates to a solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid. | 10-14-2010 |
| 20100234429 | SUBSTITUTED NICOTINAMIDES AS KCNQ2/3 MODULATORS - The invention relates to substituted nicotinamides, to processes for their preparation, to medicaments comprising these compounds and to the use of these compounds in the preparation of medicaments. | 09-16-2010 |
| 20100234428 | SUBSTITUTED 2-MERCAPTO-3-AMINOPYRIDINES AS KCNQ2/3 MODULATORS - The invention relates to substituted 2-mercapto-3-aminopyridines, methods for the preparation thereof, medicaments containing these compounds and the use of these compounds for the preparation of medicaments. | 09-16-2010 |
| 20100234421 | SUBSTITUTED 3-AMINO-2-MERCAPTOQUINOLINES AS KCNQ2/3 MODULATORS - The invention relates to substituted 3-amino-2-mercaptoquinolines, to processes for their preparation, to medicaments containing these compounds and to the use of these compounds in the preparation of medicaments. | 09-16-2010 |
| 20100234419 | SUBSTITUTED 3-AMINOISOXAZOLOPYRIDINES AS KCNQ2/3 MODULATORS - The invention relates to substituted 3-aminoisoxazolopyridines, to processes for their preparation, to medicaments containing these compounds and to the use of these compounds in the preparation of medicaments. | 09-16-2010 |
| 20100234372 | SUBSTITUTED 2-MERCAPTOQUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS - The invention relates to substituted 2-mercaptoquinoline-3-carboxamides, methods for the preparation thereof, medicaments containing these compounds and the use of these compounds for the preparation of medicaments. | 09-16-2010 |
| 20100181705 | STAR DISTRIBUTOR - The present invention relates to a device for distributing tablet blanks to the dies of a tablet press. The present invention moreover relates to a system consisting of the device according to the invention and a tablet press and to a method for forming tablets from tablet blanks. | 07-22-2010 |
| 20100152234 | Substituted 4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators - The invention relates to substituted tetrahydroisoquinolinyl-4-oxobutyric acid amides, methods for the preparation thereof, medicinal products containing these compounds and the use of these compounds for the preparation of medicinal products. | 06-17-2010 |
| 20100151028 | CRUSH RESISTANT DELAYED-RELEASE DOSAGE FORMS - The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substance (A) from the dosage form is at least partially delayed. | 06-17-2010 |
| 20100133718 | METHOD FOR THE PRODUCTION OF A FORM OF ADMINISTRATION OF A MEDICAMENT - The present invention relates to a method for producing a medicament dosage form which consists of at least one piece which in each case comprises at least one medicament and at least one additive, the medicament and the additive being mixed and extruded from a die as a strand and the strand being cut into pieces of precise weight. The invention additionally relates to a device. | 06-03-2010 |
| 20100063014 | DRUG COMPRISING AT LEAST ONE GESTAGEN - The present invention relates to the use of at least one gestagen selected from the group consisting of chlormadinone acetate, 3α-hydroxy-6-chloro-17α-acetoxy-4,6-pregnadien-20-one (3α-hydroxy-chlormadinone acetate) and 3β-hydroxy-6-chloro-17α-acetoxy-4,6-pregnadien-20-one (3β-hydroxy-chlormadinone acetate) as gestagen component and optionally at least one oestrogen selected from the group consisting of ethinyl oestradiol, oestrone, oestriol as oestrogen component and oestradiol to produce a medicament for the treatment and/or prevention of melasma and optionally for simultaneous hormonal contraception or optionally for simultaneous hormone replacement for women. | 03-11-2010 |
| 20100009986 | SUBSTITUTED HETEROARYL DERIVATIVES - The invention relates to substituted heteroaryl derivatives, to methods for the production thereof, to medicaments containing said compounds and to the use of substituted heteroaryl derivatives for producing medicaments. | 01-14-2010 |
| 20090318720 | Process for selectively synthesising 3 alpha-hydroxychlormadinone acetate - The invention relates to a process for synthesising 3α-hydroxychlormadinone acetate. | 12-24-2009 |
| 20090318395 | 3-HYDROXYCHLORMADINONE ACETATE FOR THE TOPICAL TREATMENT OF ANDROGEN-DEPENDENT SKIN DISEASES - The present invention relates to the use of 3β-hydroxychlormadinone acetate (17α-acetoxychloropregna-4,6-dien-3β-ol-20-one) and/or 3α-hydroxychlormadinone acetate (17α-acetoxychloropregna-4,6-dien-3α-ol-20-one) for producing a medicament for treating skin, preferably human skin by means of topical application, and to a pharmaceutical or cosmetic composition containing 3β-hydroxy-chlormadinone acetate and/or 3α-hydroxychlormadinone acetate. | 12-24-2009 |
| 20090312296 | ACTIVE INGREDIENT COMBINATION OF A RETINOID AND A HORMONE COMBINATION WITH CONTRACEPTIVE ACTION AS MEDICAMENT FOR TREATMENT OF SKIN DISEASES - The present invention relates to a medicament, the active ingredient combination of which consists of a retinoid selected from the group consisting of acitretin [9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid], etretinate [ethyl 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate], isotretinoin [3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid] and tretinoin [3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid] and of a hormone combination with contraceptive action of an oestrogen component and a gestagen component, and to a dosage form consisting of at least 28 daily units, of which the final 7-3 daily units contain only the retinoid as active ingredient and the other daily units also contain the hormone-containing active ingredient combination, and to the use thereof for treating acne, seborrhoea or psoriasis. | 12-17-2009 |
| 20090264387 | ESTRA-1,3,5(10)-TRIENE DERIVATIVES FOR CONTRACEPTION - The invention relates to pharmaceutical compositions and administration forms, which contain compounds of the general formula (I) | 10-22-2009 |
| 20090258948 | PHARMACEUTICAL SALTS - The invention relates to pharmaceutical salts comprised of a pharmaceutical active substance and of at least one sugar substitute, to medicaments containing these salts, and to the use of these salts for producing medicaments. | 10-15-2009 |
| 20090247591 | SUBSTITUTED CYCLOHEXYLDIAMINES - The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain or other conditions. | 10-01-2009 |
| 20090247573 | (HETERO)ARYL CYCLOHEXANE DERIVATIVES - The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions. | 10-01-2009 |
| 20090247561 | SUBSTITUTED SPIROCYCLIC CYCLOHEXANE DERIVATIVES - The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions. | 10-01-2009 |
| 20090247530 | SUBSTITUTED 4-AMINOCYCLOHEXANE DERIVATIVES - The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions. | 10-01-2009 |
| 20090247505 | SPIRO(5.5)UNDECANE DERIVATIVES - The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions. | 10-01-2009 |
| 20090215828 | Substituted indole derivatives - Substituted indole derivatives, processes for the preparation thereof, medicinal products and pharmaceutical compositions containing these compounds and the use of substituted indole derivatives to treat pain and other conditions and for other medical purposes. | 08-27-2009 |
| 20090215725 | Substituted 4-aminocyclohexane derivatives - Substituted 4-aminocyclohexane derivatives having the formula I: | 08-27-2009 |
| 20090202634 | PHARMACEUTICAL DOSAGE FORM - The invention relates to a pharmaceutical dosage form, preferably with controlled release of a pharmacologically active compound (A) contained therein, the pharmaceutical dosage form very preferably being tamper-resistant and most preferably having a breaking strength B | 08-13-2009 |
| 20090182020 | SUBSTITUTED BIS(HETERO)AROMATIC N--ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS - The present invention relates to substituted bis(hetero)aromatic N-ethylpropiolamides, methods for the production thereof, medicaments containing these compounds and the use thereof for the production of medicaments. | 07-16-2009 |
| 20090176756 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS - The present invention relates to substituted thiazoles, to methods for the production thereof, to medicaments containing these compounds and to the use thereof for producing medicaments. | 07-09-2009 |
| 20090156593 | Spirocyclic Azaindole Derivatives - The invention relates to substituted azaindole derivatives, to methods for the production thereof, to medicaments containing said compounds and to the use of substituted azaindole derivatives for producing medicaments. | 06-18-2009 |
| 20090118245 | MEDICAMENT - The present invention relates to a medicament which contains as the active ingredient combination at least one gestagen with a contraceptive action as the sole hormone component and at least one insulin sensitiser, which medicament is in particular suitable for preventing or treating pathological disorders which are caused by polycystic ovary syndrome (PCOS). | 05-07-2009 |
| 20090093448 | 19-NOR-PROGESTERONE FOR CONTRACEPTION - The invention relates to compounds of the general formula (I) | 04-09-2009 |
| 20090075978 | SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS - The present invention relates to substituted propiolic acid amides, to methods for the production thereof, to medicaments containing these compounds and to the use thereof for producing medicaments. | 03-19-2009 |
| 20090023694 | Contraceptive - The present invention relates to an administration form for hormonal contraception consisting of a particular number of hormone-containing daily units, comprising a hormone combination consisting of at least one oestrogen selected from the group comprising ethinyl oestradiol (I) and oestradiol (II) as the oestrogen component, and at least one metabolite of chlormadinone acetate selected from the group comprising 3α-hydroxy-6-chloro-17α-acetoxy-4,6-pregnadien-20-one (3α-hydroxy-chlormadinone acetate), 3β-hydroxy-6-chloro-17α-acetoxy-4,6-pregnadien-2-one (3β-hydroxy-chlormadinone acetate), optionally mixed with chlormadinone acetate and/or 3α-hydroxy-17α-acetoxy-5β-pregnan-20-one and/or 3β-hydroxy-17α-acetoxy-5β-pregnan-20-one as the gestagen component for the uninterrupted, daily, oral administration of the hormone-containing daily units, optionally in combination with 7 to 3 hormone-free daily units. | 01-22-2009 |
| 20090005408 | PROCESS FOR THE PRODUCTION OF AN ABUSE-PROOFED DOSAGE FORM - The present invention relates to a process for the production of abuse-proofed, thermoformed dosage forms containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N. | 01-01-2009 |
| 20080317854 | PROCESS FOR THE PRODUCTION OF AN ABUSE-PROOFED SOLID DOSAGE FORM - The present invention relates to a process for the production of an abuse-proofed solid dosage form containing at least one active ingredient with potential for abuse and a binder with a breaking strength of =500 N, by exposing a mixture comprising the active ingredient and the binder to ultrasound and force. | 12-25-2008 |
| 20080312264 | Process for the production of an abuse-proofed solid dosage form - The present invention relates to a process for the production of an abuse-proofed solid dosage form containing at least one active ingredient with potential for abuse and a synthetic or natural polymer with a breaking strength of =500 N, characterised in that a corresponding mixture is processed by melt extrusion with the assistance of a planetary-gear extruder. | 12-18-2008 |
| 20080312200 | Medicament Comprising A Hormone Combination - The present invention relates to the use of a hormone combination of ethinyl oestradiol or oestradiol as oestrogen component and at least one metabolite of chlormadinone acetate selected from the group consisting of 3α-hydroxy-6-chloro-17α-acetoxy-4,6-pregnadien-20-one (3α-hydroxychlormadinone acetate), 3β-hydroxy-6-chloro-17α-acetoxy-4,6-pregnadien-20-one (3β-hydroxychlormadinone acetate), 3α-hydroxy-17α-acetoxy-5β-pregnan-20-one and 3β-hydroxy-17α-acetoxy-5β-pregnan-20-one, optionally mixed with chlormadinone acetate as gestagen component for producing a medicament at least for alleviating menstrual cycle-dependent mood swings and optionally for hormonal contraception in women. | 12-18-2008 |
| 20080311197 | PROCESS FOR THE PRODUCTION OF AN ABUSE-PROOFED DOSAGE FORM - The present invention relates to a process for the production of an abuse-proofed dosage form containing, apart from one or more active ingredients with potential for abuse and optionally physiologically acceptable auxiliary substances, at least one synthetic or natural polymer (C) with a breaking strength of at least 500 N, wherein the formulation mixture is combined with a solvent for the polymer (C) at least in quantities such that the formulation mixture is at least uniformly moistened, the at least moistened composition is optionally divided into sub-portions, dried and shaped to yield the dosage form. | 12-18-2008 |
| 20080311187 | CRUSH RESISTAN DELAYED-RELEASE DOSAGE FORM - The invention relates to a dosage form comprising a physiologically effective amount of a physiologically active substance (A), a synthetic, semi-synthetic or natural polymer (C), optionally one or more physiologically acceptable auxiliary substances (B) and optionally a synthetic, semi-synthetic or natural wax (D), wherein the dosage form exhibits a resistance to crushing of at least 400 N and wherein under physiological conditions the release of the physiologically active substances (A) from the dosage form is at least partially delayed. | 12-18-2008 |
| 20080311049 | ABUSE-PROOF DOSAGE FORM - The invention relates to a dosage form that is thermoformed without discoloration and is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse. The invention also relates to a corresponding method for producing said dosage form. | 12-18-2008 |
| 20080269497 | Hydrates of Optionally Substituted 2-(2-Pyridinyl) Methylthio-1H-Benzimidazoles and Process for the Production Thereof - The invention relates to crystals from optionally substituted 2-(2-pyridinyl)methylthio-1H-benzimidazole hydrates and to a method for the production thereof. | 10-30-2008 |
| 20080269295 | SUBSTITUTED THIAZOLES AND THEIR USE FOR PRODUCING DRUGS - The present invention relates to substituted thiazoles, to methods for their production, to drugs containing these compounds and to the use of said compounds for producing drugs. | 10-30-2008 |
| 20080261996 | Substituted propiolic acid amides and their use for producing drugs - The present invention relates to substituted propiolic acid amides, methods for the production thereof, medicaments containing these compounds and the use thereof for producing medicaments. | 10-23-2008 |
| 20080248113 | ABUSE-PROOFED ORAL DOSAGE FORM - The present invention relates to an abuse-proofed, oral dosage form with controlled opioid-release for once daily administration, characterised in that it comprises at least one opioid with potential for abuse (A), at least one synthetic or natural polymer (C), optionally delayed-release matrix auxiliary substances, physiologically acceptable auxiliary substances (B), optionally a wax (D) and optionally at least one delayed-release coating, component (C) or (D) in each case exhibiting a breaking strength of at least 500 N, preferably of at least 1000 N. | 10-09-2008 |
| 20080247959 | FORM OF ADMINISTRATION SECURED AGAINST MISUSE - The invention relates to a form of administration which is thermoformed without extrusion, comprising at least one synthetic or natural polymer having a resistance to breaking of at least 500 N in addition to one or several active ingredients with a misuse potential and, optionally physiologically compatible auxiliary substances. The invention also relates to a method for the production thereof. | 10-09-2008 |
